CDK7 inhibition augments response to multidrug chemotherapy in pancreatic cancer

CDK7 inhibition augments response to multidrug chemotherapy in pancreatic cancer

Abstract Background Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with a dismal prognosis. Although combined treatment with gemcitabine and albumin-bound paclitaxel has improved the prognosis of PDAC, both intrinsic and acquired chemoresistance remain as severe hurtles towards impr...

Full description

Bibliographic Details
Main Authors: Siyuan Zeng, Bin Lan, Xiaofan Ren, Shuman Zhang, Daniel Schreyer, Markus Eckstein, Hai Yang, Nathalie Britzen-Laurent, Andreas Dahl, Debabrata Mukhopadhyay, David Chang, Isabella Kutschick, Susanne Pfeffer, Peter Bailey, Andrew Biankin, Robert Grützmann, Christian Pilarsky
Format: Article
Language:English
Published: BMC 2022-08-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
CRISPR-Cas9
CDK7
Gemcitabine
Paclitaxel
FOLFIRINOX
THZ1
Online Access:https://doi.org/10.1186/s13046-022-02443-w

Internet

https://doi.org/10.1186/s13046-022-02443-w

Similar Items